Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm and semiconductor stocks. However, market leadership was uneven, with high-beta stocks outperforming while quality companies lagged, affecting Conestoga’s strategies. Management is confident that speculative leadership won’t endure as monetary policy tightens and expects high-quality growth businesses to regain prominence as market leadership broadens. The Conestoga SMid Cap Composite returned 7.04% (net) in the second quarter, underperforming the Russell 2500 Growth Index, which returned 24.02%. A combination of factor and sector-specific headwinds drove the underperformance, along with stock selection challenges, particularly within Technology and Industrials. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted West Pharmaceutical Services, Inc. (NYSE:WST) as a performance contribtor. West Pharmaceutical Services, Inc. (NYSE:WST) is a leading manufacturer and distributor of containment and delivery systems for injectable drugs and healthcare products. On August 5, 2026, West Pharmaceutical Services, Inc. (NYSE:WST) closed at $351.02 per share, reflecting a market capitalization of $24.7 billion. West Pharmaceutical Services, Inc. (NYSE:WST) posted a one-month return of -1.86%, while its shares gained 45.93% over the past 52 weeks.
Conestoga Capital Advisors stated the following regarding West Pharmaceutical Services, Inc. (NYSE:WST) in its Q2 2026 investor letter:
“West Pharmaceutical Services, Inc. (NYSE:WST) develops drug containment and delivery systems for injectable pharmaceuticals and biologic therapies. The stock moved higher following another quarter of broad based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Organic revenue increased 15%, and management reinstated its favorable long-term growth outlook as strong demand from biologics and GLP-1 therapies continues to support growth across the portfolio. This quarter seemingly signaled a return to normalized growth rates following several years of post-COVID de-stocking.”
West Pharmaceutical Services, Inc. (NYSE:WST) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 50 hedge fund portfolios held West Pharmaceutical Services, Inc. (NYSE:WST) at the end of the first quarter, compared to 57 in the previous quarter. While we acknowledge the risk and potential of West Pharmaceutical Services, Inc. (NYSE:WST) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than West Pharmaceutical Services, Inc. (NYSE:WST) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered West Pharmaceutical Services, Inc. (NYSE:WST) and shared a list of most profitable dividend stocks to invest in. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
